Baseline data of the study population (n=1531)*†
| Gender | |
| Female | 750 (49.20%) |
| Age | 61.37 (10.90) |
| Educational level | |
| Low | 699 (53.60%) |
| Middle | 467 (35.80%) |
| High | 138 (10.60%) |
| Diabetes duration (years) | 7.00 (4.00–12.00) |
| Complications | |
| 0 | 881 (62.70%) |
| ≥1 | 523 (37.30%) |
| Comorbidities | |
| 0 | 1367 (89.30%) |
| ≥1 | 164 (10.70%) |
| HbA1c | |
| mmol/mol | 69.32 (16.45) |
| % | 8.49 (1.51) |
| Body mass index | 30.53 (6.27) |
| Treatment | |
| Oral agents | 1021 (66.70%) |
| Insulin | 510 (33.30%) |
| Symptomatic hypoglycemia during the past 3 months (self-report) | |
| 0 episode | 584 (48.90%) |
| ≥1 episode | 610 (51.10%) |
| Severe hypoglycemia during the past 3 months (self-report) | |
| 0 episode | 1191 (94.30%) |
| ≥1 episode | 72 (5.70%) |
| WHO-5 score (well-being) | 60.00 (40.00–76.00) |
*Based on non-imputed data.
†For categorical variables: frequencies (valid percentages); for normally distributed continuous variables: mean (SD); for skewed distributed continuous variables: median (25th–75th percentile).
HbA1c, hemoglobin A1c.